

Eisai is a Human Health Care Corporation striving for innovative solutions in prevention, cure and care for the health and well-being of people worldwide. We combine our talents to understand and meet the needs of patients and their families to enhance the quality of life.

FOR IMMEDIATE RELEASE

No. 09-30

July 27, 2009

Eisai Co., Ltd.

**Eisai Files Submission to Health Authorities in Switzerland for E7389,
Novel Anti-cancer Agent, for the Treatment
of Metastatic and Locally Advanced Breast Cancer**

Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") announced today that its Swiss subsidiary, Eisai Pharma AG (Location: Zurich, Switzerland, Director: Folker Kindl), has submitted to the health authorities (Swissmedic) marketing authorisation applications for eribulin mesylate ("eribulin"), also known as E7389, seeking approval for this novel anti-cancer agent as a treatment for locally advanced and metastatic breast cancer. This submission was made with data derived primarily from Study 211 (Phase II trial).

Eribulin, a microtubule dynamics inhibitor, is a new chemical compound discovered and developed by Eisai. It is believed to exert an anti-tumour effect by arresting the cell cycle through inhibition of the growth of microtubules, which are involved in intracellular processes such as cell division. Eribulin is

